Duncan Jason 4
4 · ALBIREO PHARMA, INC. · Filed Jan 20, 2023
Insider Transaction Report
Form 4
Duncan Jason
General Counsel
Transactions
- Sale
Common Stock
2023-01-19$43.90/sh−938$41,182→ 14,374 total
Footnotes (3)
- [F1]Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $43.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]Represents 2,867 shares of common stock and 11,507 restricted stock units. Includes 381 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on November 30, 2022.